

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Agrawal et al.

Art Unit:

1635

Serial No.:

09/777,526

Examiner:

Gibbs, Terra C.

Filing Date:

February 6, 2001

Customer No:

23483

Title:

Method of Down-Regulating Gene

Expression

Conf. No:

8659

Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TERMINAL DISCLAIMER

Dear Sir:

I, Ann-Louise Kerner, Ph.D., declare that I am an attorney of record for Hybridon, Inc., the assignee of all rights and interest in the above-referenced patent application, as recorded on Reel 8507, Frame 0358, that the evidentiary documents have been reviewed and that I certify, to the best of my knowledge and belief, title is in Hybridon, Inc., and that I am authorized to execute this Terminal Disclaimer on behalf of Hybridon, Inc.

Pursuant to 35 U.S.C. § 253 and 37 C.F.R. § 1.321, Hybridon, Inc. hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory term of prior United States Letters Patent No. 5,591,721, and hereby agrees that any patent so granted on the subject application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to prior United States Letters Patent No. 5,591,721, this

03/24/2004 MAHNED1 00000107 080219 09777526

03 FC:2814

55,000 M1874319v1

/シラ /

Page 2

agreement to run with any patent granted on the subject application and to be binding upon the grantee, its successors or assigns.

Petitioner does not disclaim any terminal part of any patent granted on the subject application prior to the expiration date of the full statutory term of prior United States Letters Patent No. 5,591,721, in the event that the latter expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321, has all claims cancelled by a reexamination certificate, is reissued or is otherwise terminated prior to expiration of its statutory term as presently shortened by any terminal disclaimer.

The Commissioner is authorized to charge Deposit Account No. 08-0219 the fee of \$55.00 as required by 37 C.F.R. § 1.20(d) for filing terminal disclaimers. No other fees are believed to be due in connection with this paper. However, please charge any fees, or credit any overpayment, that may be due in connection with this paper to Deposit Account No. 08-0219.

Respectfully submitted, HALE AND DORR LLP

Ann-Louise Kerner, Ph.D.

Reg. No. 33,523

Date: March 22, 2004 HALE AND DORR LLP 60 State Street Boston, MA 02109 Tel. (617) 526-6000 Fax (617) 526-5000